13F Holdings
中文EN

MGNX MACROGENICS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1125345 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY22.8%
TTM net income YoY32.1%
TTM EPS YoY33.9%
Revenue 3-yr CAGR-2.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-70.2%
Net margin-45.4%
FCF margin-36.4%
EBITDA margin-66.4%

Returns

ROE-111.8%
ROA-17.5%
ROIC (approx.)—
Asset turnover0.39x

Leverage & solvency

Liabilities / assets92.1%
Debt / equity0.00x
Current ratio2.75x
Interest coverage-4.52x

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-3.9%
Payout ratio—
Capex / revenue1.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$149.50M$149.96M$58.75M$151.94M$77.45M
Cost of revenue$0$847,000$619,000$3.35M$2.65M
Gross profit$149.50M$149.12M$58.13M$148.59M$74.80M
R&D expense$147.17M$177.19M$166.58M$207.03M$214.58M
SG&A expense$39.16M$71.05M$52.19M$58.95M$63.01M
Operating income-$72.84M-$110.58M-$168.24M-$121.42M-$202.79M
Interest expense$8.51M$1.11M$1.43M$0$0
Pretax income-$75.29M-$66.02M-$9.06M-$119.76M—
Income tax-$672,000$944,000$0$0$0
Net income-$74.62M-$66.97M-$9.06M-$119.76M-$202.12M
EBITDA-$65.67M-$103.04M-$158.60M-$109.55M-$191.54M
EPS (basic)-1.18-1.07-0.15-1.95-3.37
EPS (diluted)-1.18-1.07-0.15-1.95-3.37
Weighted avg. shares (diluted)63.16M62.62M61.93M61.43M59.94M
Balance sheet
Cash & equivalents$57.22M$182.84M$100.96M$108.88M$123.47M
Receivables$427,000$4.31M$10.37M$56.22M$10.39M
Inventory$7.91M$0$1.22M$1.45M$4.39M
Current assets$219.94M$217.49M$251.34M$222.18M$279.56M
PP&E, net$2.10M$18.10M$21.85M$29.57M$37.68M
Total assets$256.85M$261.65M$298.42M$280.47M$335.25M
Current liabilities$43.12M$55.53M$56.11M$48.61M$74.58M
Total liabilities$201.25M$145.60M$145.81M$138.46M$95.63M
Shareholders' equity$55.59M$116.06M$152.61M$142.01M$239.62M
Shares outstanding63.32M62.82M62.07M61.70M61.31M
Cash flow statement
Operating cash flow-$81.04M-$68.37M-$78.20M-$86.96M-$143.83M
Capital expenditure$1.91M$3.71M$1.76M$3.62M$6.20M
Free cash flow-$82.95M-$72.08M-$79.97M-$90.58M-$150.03M
Investing cash flow-$114.10M$149.30M-$80.08M$70.72M-$36.61M
Financing cash flow$69.51M$960,000$150.36M$1.66M$122.78M
Depreciation & amortization$7.17M$7.54M$9.64M$11.87M$11.26M
Stock-based compensation$14.29M$29.44M$18.37M$20.44M$23.13M

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.